Evidence map›Paper›PMID 30468032›Full record

ArticleKorean circulation journal2019

Infliximab Treatment for Intravenous Immunoglobulin-resistant Kawasaki Disease: a Multicenter Study in Korea.

Gyu Hur, Min Seob Song, Sejung Sohn, Hyoung Doo Lee, Gi Beom Kim, Hwa Jin Cho, Kyung Lim Yoon, Chan Uhng Joo, Myung Chul Hyun, Chul Ho Kim

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Korean circulation journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. TNF-α blockers for the treatment of Kawasaki disease in children.The Cochrane database of systematic reviews · 2019
    Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 1 country.

Gyu HurDepartment of Pediatrics, Inje University, Haeundae Paik Hospital, Busan, Korea.
Min Seob SongDepartment of Pediatrics, Inje University, Haeundae Paik Hospital, Busan, Korea. msped@hanmail.net.ORCID https://orcid.org/0000-0003-3426-6803
Sejung SohnDepartment of Pediatrics, Ewha Womans University, Mokdong Hospital, Seoul, Korea.ORCID https://orcid.org/0000-0001-9960-7774
Hyoung Doo LeeDepartment of Pediatrics, Busan National University, Children's Hospital, Busan, Korea.ORCID https://orcid.org/0000-0002-6125-187X
Gi Beom KimDepartment of Pediatrics, Seoul National University, Children's Hospital, Seoul, Korea.ORCID https://orcid.org/0000-0002-7880-280X
Hwa Jin ChoDepartment of Pediatrics, Chonnam National University, Children's Hospital, Gwangju, Korea.ORCID https://orcid.org/0000-0002-2458-8529
Kyung Lim YoonDepartment of Pediatrics, Kyung Hee University Hospital at Gangdong, Seoul, Korea.ORCID https://orcid.org/0000-0003-4734-900X
Chan Uhng JooDepartment of Pediatrics, Chonbuk National University Medical School, Children's Hospital, Cheonju, Korea.
Myung Chul HyunDepartment of Pediatrics, Kyungpook National University, School of Medicine, Daegu, Korea.
Chul Ho KimDepartment of Pediatrics, Inje University, Busan Paik Hospital, Busan, Korea.
Inje University Haeundae Paik Hospital · KRBusan National University of Education · KRChonnam National University Hospital · KREwha Womans University · KRInje University Busan Paik Hospital · KRJeonbuk National University Hospital · KRKyung Hee University Hospital at Gangdong · KRKyungpook National University · KRSeoul National University Children's Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesWe investigated the status of infliximab use in intravenous immunoglobulin (IVIG)-resistant Kawasaki disease (KD) patients and the incidence of coronary artery aneurysms (CAAs) according to treatment regimens.

methodsBetween March 2010 and February 2017, 16 hospitals participated in this study. A total of 102 (32.3±19.9 months, 72 males) who received infliximab at any time after first IVIG treatment failure were enrolled. Data were retrospectively collected using a questionnaire.

resultsSubjects were divided into two groups according to the timing of infliximab administration. Early treatment (group 1) had shorter fever duration (10.5±4.4 days) until infliximab infusion than that in late treatment (group 2) (16.4±4.5 days; p<0.001). We investigated the response rate to infliximab and the incidence of significant CAA (z-score >5). Overall response rate to infliximab was 89/102 (87.3%) and the incidence of significant CAA was lower in group 1 than in group 2 (1/42 [2.4%] vs. 17/60 [28.3%], p<0.001).

conclusionsThis study suggests that the early administration of infliximab may reduce the incidence of significant CAA in patients with IVIG-resistant KD. However, further prospective randomized studies with larger sample sizes are required.

Indexed as

Coronary arteryInfliximabIntravenous immunoglobulinsKawasaki disease

Identifiers

PMID30468032
PMCPMC6351283
OpenAlexW2898045891

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.